Revvity to exit China Immunodiagnostics business as Q1 sales beat estimates

Revvity (NYSE:RVTY) exceeded Wall Street estimates for the first quarter and unveiled a major strategic pivot, announcing its intention to divest its China Immunodiagnostics business to sharpen its focus on high-growth life sciences and specialty diagnostics.

The Waltham, Massachusetts-based company reported first-quarter revenue of $711 million, a 7% increase over the prior year.

Organic revenue growth stood at 3%, while pro forma organic growth—which excludes the impact of the business slated for divestiture—rose 6%.

The results were supported by an 8% climb in the Diagnostics segment and a 6% rise in Life Sciences revenue.

Profitability also came in ahead of expectations.

Revvity reported adjusted earnings per share (EPS) from continuing operations of $1.06, surpassing the analyst consensus of $1.02.

On a GAAP basis, EPS from continuing operations was $0.37, compared to $0.35 in the same period last year.

The highlight of the report was the signing of a letter of intent to sell the China Immunodiagnostics business for up to $200 million.

The unit represented approximately 6% of the company’s 2025 revenue but has faced headwinds from evolving regional policies and pricing pressures.

The sale is targeted to close in 2027.

Following the announcement, Revvity updated its full-year 2026 guidance on a pro forma basis to reflect the pending exit.

The company now expects pro forma revenue in the range of $2.81 billion to $2.84 billion, representing pro forma organic growth of 3% to 4%.

Full-year pro forma adjusted EPS is projected to be between $5.20 and $5.30.